National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Gilteritinib (Xospata®)  as monotherapy is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an FLT3 mutation.

NCPE Assessment Process Complete
Rapid Review commissioned 14/10/2019
Rapid Review completed 29/11/2019
Rapid Review Outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of gilteritinib compared with the current standard of care.